STRASBOURG, France & TOKYO--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ...

Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...

-- Longitudinal analysis of GRANITE recipients (personalized vaccine candidate now in Phase 2/3 for MSS-CRC) demonstrates vaccine-elicited priming and boosting of antigen-specific T cell populations ...

Traditional neoantigen prediction methods primarily rely on HLA-peptide binding databases, often producing false positives. This challenge highlights the need for improved strategies to identify truly ...

The FDA has cleared Everest Medicine's EVM14 cancer vaccine application, and its EVM16 vaccine has been administered on the first patient under an investigator-initiated trial Everest Medicines has ...